The role of NfL in the diagnosis, prognosis, and treatment response evaluation has been investigated mostly in patients with MS, which is one of the neuroinflammatory diseases [4,10-12], and continues to be investigated with increasing interest not only in MS, but also in spinal cord trauma, Alzheimer’s disease, and frontotemporal dementia [13-16]. This evidence concerns the gene NEFL and myeloid sarcoma.